(Q35561206)

8 August 2017

title

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). (English)

1 reference

8 August 2017

0 references

1 reference

8

Jean-Louis Vincent

1 reference

8 August 2017

1

Andrew F Shorr

1 reference

8 August 2017

13

Konrad Reinhart

1 reference

8 August 2017

Jonathan M Janes

2

1 reference

8 August 2017

Antonio Artigas

3

1 reference

8 August 2017

Jyrki Tenhunen

4

1 reference

8 August 2017

Duncan L A Wyncoll

5

1 reference

8 August 2017

Emmanuelle Mercier

6

1 reference

8 August 2017

Bruno Francois

7

1 reference

8 August 2017

Burkhard Vangerow

9

1 reference

8 August 2017

Darell Heiselman

10

1 reference

8 August 2017

Amy G Leishman

11

1 reference

8 August 2017

Yajun E Zhu

12

1 reference

8 August 2017

RESPOND investigators

14

1 reference

8 August 2017

publication date

21 December 2010

1 reference

8 August 2017

1 reference

8 August 2017

volume

14

1 reference

8 August 2017

issue

6

1 reference

8 August 2017

page(s)

R229

1 reference

The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Protein C as a surrogate end-point for clinical trials of sepsis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

The protein C pathway: implications for the design of the RESPOND study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Efficacy and safety of recombinant human activated protein C for severe sepsis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Protein S and C alterations in acutely ill patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Severe protein C deficiency predicts early death in severe sepsis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Low levels of protein C are associated with poor outcome in severe sepsis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3219981

Protein C Concentrations Correlate with Organ Dysfunction and Predict Outcome Independent of the Presence of Sepsis

26 September 2018

1 reference

12 December 2020

The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock

1 reference

12 December 2020

Time course of hemostatic abnormalities in sepsis and its relation to outcome.

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

12 December 2020

Identifiers

DOI

10.1186/CC9382

1 reference

Dimensions Publication ID

8 August 2017

0 references

1 reference

8 August 2017

1 reference